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Introduction {#sec1-1}
============

Down syndrome, also known as trisomy 21, is one of the most common chromosomal diseases. In 1886, British doctor Lang Down first described the clinical symptoms of the disorder, but it was not until 1959 that this disease was found to be caused by a third copy of chromosome 21. According to epidemiologic studies, the incidence of Down syndrome is about 1/700, with about 200,000 new cases worldwide each year (Heller et al., 2014). In recent years, with the popularity of noninvasive prenatal DNA screening, the number of Down syndrome births has dropped dramatically. Attention has been increasingly focused on the treatment and improvement of the quality of life of the population with Down syndrome. The cognitive deficits in Down syndrome appear to be caused by abnormal neurogenesis, impaired synaptic plasticity and neurochemical changes (Lott and Dierssen, 2010; Dierssen, 2012).

Learning and memory are major functions of the central nervous system and are vital for adaptation and survival. The hippocampal formation is a key brain area involved in learning and memory. A substructure of the hippocampus, the dentate gyrus is a major site of adult neurogenesis and synaptic plasticity, both of which are critical for learning and memory (Snyder et al., 2001; Schmidt-Hieber et al., 2004; Ge et al., 2008).

Over the past few years, an increasing number of studies have explored the exciting possibility of using pharmacological approaches to ameliorate neuronal developmental deficits in Down syndrome mouse models, and a great deal of progress has been made. Studies using the Ts65Dn mouse model have reported that neurogenesis is reduced in the adult dentate gyrus, and that neurogenesis promoting drugs, such as fluoxetine (Clark et al., 2006) and lithium (Contestabile et al., 2013), enhance the proliferation of neural precursor cells in the dentate gyrus. Another study showed that combined environmental enrichment and epigallocatechin gallate therapy in young Ts65Dn mice improved cortico--hippocampal-dependent learning and memory (Catuara-Solarz et al., 2016). Together, these recent studies show that Down syndrome symptoms can be alleviated by appropriate drug treatment.

Natural phytochemicals, including flavones, have been evaluated for their neuroprotective and neurotrophic activities. Flavonoids have various beneficial effects, including scavenging free radicals, alleviating cognitive impairment, and improving learning and memory (Bhullar and Rupasinghe, 2013). For example, baicalein increases the expression levels of phospho-extracellular signal-regulated kinase (p-ERK), phospho-cAMP-response element binding protein and brain-derived neurotrophic factor (BDNF) (Park et al., 2010). Oral administration of the flavonoid chrysin prevents age-associated memory loss, probably by scavenging free radicals and modulating BDNF production (Souza et al., 2015). Curcumin protects against behavioral impairments, neuroinflammation, tau hyperphosphorylation and cell signaling disturbances triggered by amyloid beta *in vivo* (Hoppe et al., 2013). Furthermore, the BDNF mimetic 7,8-dihydroxyflavone alleviates intellectual disabilities in a Down syndrome model (Jang et al., 2010).

Luteolin (3′,4′, 7-tetrahydroxyflavone), a natural flavonoid, is widely distributed in honeysuckle, chrysanthemum, *Dracocephalum ruyschiana* and other plants, and has antioxidant, anti-inflammatory and other pharmacological effects. It is clinically used to treat tumors, hepatitis, hypertension, and amyotrophic lateral sclerosis (Lin et al., 2008; Jiang et al., 2013). Luteolin was shown to protect dopaminergic neurons from LPS-induced injury, perhaps by inhibiting microglial activation (Chen et al., 2008). In the PC12 cell line, luteolin induces neurite outgrowth and augments cellular antioxidant defense capacity through the activation of the ERK signaling pathway (Lin et al., 2010).

In the present study, we investigated the effect of luteolin on neurogenesis in the dentate gyrus of Ts65Dn mice, and we examined the underlying mechanisms of action.

Materials and Methods {#sec1-2}
=====================

Animals and luteolin treatment {#sec2-1}
------------------------------

Three Ts65Dn breeder pairs of mice (Stock No. 001924) were purchased from The Jackson Laboratories (Bar Harbor, ME, USA). Females trisomic for distal chromosome 16 (Ts65Dn) were bred to B6EiC3SnF1/J F1 hybrid male mice and housed in a quiet room at 25°C under a standard 12-hour light/dark cycle. All the females were kept as breeders for colony maintenance, and their offspring, including Ts65Dn and wild-type (WT) euploid littermates, were genotyped according to the protocol provided by Jackson Laboratories.

When the mice were at the age of 12 weeks, Ts65Dn and WT euploid littermate males were randomly assigned to the following groups: WT + vehicle group (*n* = 25), WT + luteolin group (*n* = 22), Ts65Dn + vehicle group (*n* = 20), and Ts65Dn + luteolin group (*n* = 20).

Luteolin was purchased from Sigma-Aldrich (98% purity) and dissolved in saline. According to a previously published method (Yoo et al., 2013), every morning the mice received an intraperitoneal injection of luteolin (or vehicle, 0.9% saline) 10 mg/kg, for 4 weeks. All animal experiments were performed in accordance with the Guide for the Care and Use of Laboratory Animals, and were approved by the Jiangsu University Laboratory Animal Management Committee (approval No. UJS-LAER-2017042201) on April 22, 2017.

Morris water maze test {#sec2-2}
----------------------

After administration of luteolin for 4 weeks, the water maze test was performed as previously described (Cuadrado-Tejedor et al., 2011). The water maze experiment device (RD1101-MWM-G, Mobiledatum, Shanghai, China) was a stainless-steel sink, with a diameter of 100 cm and a height of 50 cm, containing four quadrants. A circular platform with a diameter of 9 cm and a height of 27 cm was in the center of the platform quadrant, and its position remained unchanged throughout the experiment. Milk was added to the pool to make the water opaque. Water temperature was kept at 23°C. After the mice were adjusted in a quiet test room for 1 hour, the experiment was conducted. On the first day, a visual platform experiment was carried out. The platform was exposed 1 cm above the water surface. Each mouse was put into the pool and allowed to swim for 2 minutes for acclimation.

During the following 2--5 days, the navigation experiment was conducted. The platform was located 1 cm under the surface of the water. The mouse was placed into the water in each of the three quadrants and allowed to swim for 1 minute each time. The mouse either found the platform and remained there for 5 seconds, or the 1-minute test time elapsed. Whether or not the mouse found the platform, it was gently guided to the platform and allowed to remain there for 15 seconds. Then, 1 day after the navigation experiment, the platform was removed for the spatial exploration test. The mouse was placed in the water in the same quadrant. The time to find the platform, the number of entries into the quadrant previously containing the platform, and the time spent in the target quadrant were recorded by an automatic video tracking system above the pool. All experiments were carried out between 9.00 a.m. and 5.00 p.m.

Novel object recognition {#sec2-3}
------------------------

Rodents have the natural habit of exploring new objects. The experiment was performed as previously described in Ts65Dn mice (Parrini et al., 2017) and tested in a black empty box, and carried out in a horizontal, quiet environment with a camera mounted 2 m above. Before the test, the mouse was placed into the empty container in the same orientation and position, and allowed to move freely for 10 minutes for acclimation (once a day for 3 consecutive days). During the 4 days of training, two similar objects were placed at the bottom of the empty box (10 cm from each side). The mouse was placed back into the box and returned to the cage after 10 minutes of free activity. After 1 hour, one of the two objects was replaced with a new object (different sizes and materials). The mouse was placed in the box, and activity was observed for a period of 10 minutes. The total time the animal spent exploring each of the objects was recorded. The behaviors recorded included the distance between the nose tip and the object when the animal sniffed the object from less than 2 cm, and the times the nose or front paw directly touched the object. Walking near the object was not considered exploratory behavior. The novel object cognitive discrimination index was defined as: time exploring the novel object/total exploratory time. A solution of 90% alcohol was used to eliminate odors between experiments (to avoid olfactory cues from affecting the exploratory behavior of other animals).

Hippocampal tissue preparation {#sec2-4}
------------------------------

After behavioral testing, the mice were weighed on an electronic scale (Hengping Scientific Instrument, Shanghai, China). All mice were anesthetized with 4% chloral hydrate. After the thoracic cavity was opened, the needle was carefully inserted through the left ventricle into the aorta, and the right atrium was cut. The mice were then perfused with 50 mL saline followed by 100 mL paraformaldehyde (4%) solution. Subsequently, the brains were gently removed, blotted dry, and quickly weighed with an electronic balance (Sartorius, Gottingen, Germany). The hippocampal tissue was then carefully removed.

Immunohistochemistry {#sec2-5}
--------------------

The hippocampal tissue was fixed with 4% paraformaldehyde for 24 hours. The tissue was then dehydrated, paraffin-embedded, dehydrated, and cut into serial coronal sections with a microtome (RM2235 Leica, Wetzlar, Germany). After dewaxing, rehydration and antigen retrieval, each paraffin section was treated with 3% H~2~O~2~-methanol solution, blocked at 15--25°C for 10 minutes, and then incubated with 100 μL goat serum at room temperature for 20 minutes.

For immunofluorescence, the following primary antibodies were used: mouse monoclonal anti-nestin (neural stem cell marker; 1:250; Abcam, Cambridge, UK), rabbit polyclonal anti-GFAP (astrocyte marker; 1:500; Abcam), rabbit polyclonal anti-DCX (immature neuron marker; 1:800; Abcam), rabbit monoclonal anti-NeuN (mature neuron marker; 1:250; Abcam) and rabbit polyclonal anti-Ki67 (cell proliferation marker; 1:250; Abcam). Each section was incubated with primary antibody for 2 hours at room temperature. After washing, sections were incubated with FITC or TRITC-conjugated goat anti-mouse or goat anti-rabbit secondary antibody (1:250; Jackson ImmunoResearch; West Grove, PA, USA). Afterwards, the sections were counterstained with DAPI and mounted in antifade medium. The immunoreactivity of protein in cells was observed under a fluorescence microscope (BX43; Olympus, Tokyo, Japan).

Cells were observed under an Olympus CX41 microscope with a 40× objective. Ki67^+^, DCX^+^ and NeuN^+^ cells covering the complete rostro-caudal extension of the dentate gyrus were quantified as previously described (Contestabile et al., 2013). Serial coronal sections with a thickness of 30 μm were obtained, and one section was selected every 200 μm for cell counting. A total of 12 sections were taken from each mouse. The positive cells in 12 sections of the hippocampal granulosa layer and the dentate gyrus were counted. For nestin and GFAP, hippocampal dentate gyrus regions from three sections were selected for each animal, and then three random visual fields were analyzed using IPP6.0 software (Media Cybernetics, Montgomery, MD, USA) at 200× magnification. Results are shown as mean density = (sum of the integrated optical density)/area.

Nissl staining {#sec2-6}
--------------

Paraffin sections were stained with Nissl staining solution (Beyotime, Shanghai, China) for 5 minutes, washed with water and then with 95% ethanol for 5 seconds. The sections were dehydrated through a graded alcohol series and xylene, and mounted with neutral balsam. The morphological and quantitative changes in neural cells in the hippocampal dentate gyrus were observed under an optical microscope (BX43, Olympus).

Western blot assay {#sec2-7}
------------------

Total protein in hippocampal tissue was extracted with a protein extraction kit (Beyotime), and protein concentration was determined using the Bradford protein concentration determination kit (Beyotime). Total protein was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Afterwards, the separated proteins were transferred onto nitrocellulose filter membranes. The blots were blocked with 5% bovine serum albumin for 2 hours at room temperature, and then incubated with the following primary antibodies at 4°C overnight: rabbit monoclonal anti-BDNF (1:1000; Abcam), rabbit polyclonal anti-p-ERK1/2 (phosphoT202+Y204; 1:1500; Abcam), rabbit polyclonal anti-ERK1/2 (1:1000; Abcam) and mouse monoclonal anti-GAPDH (1:1000; Abcam). The next day, the membranes were washed three times with phosphate-buffered saline containing Tween-20 (PBST), and then incubated with secondary antibody (horseradish peroxidase-conjugated anti-rabbit or anti-mouse IgG; 1:1000; Beyotime, Shanghai, China) for 1 hour. The blots were then washed three times with PBST, and then treated with 1--2 mL enhanced chemiluminescence reaction liquid for 1 minute. The membranes were observed and photographed with a Tanon 5200 Luminescence imaging system (Tanon, Shanghai, China). Protein expression was analyzed according to optical density.

Statistical analysis {#sec2-8}
--------------------

Data are presented as the mean ± SE. Statistical analysis was performed using SPSS v22.0 software (IBM, Armonk, NY, USA). Data were evaluated using two-way analysis of variance followed by Tukey's *post hoc* test. A value of *P* \< 0.05 was considered statistically significant.

Results {#sec1-3}
=======

Effect of luteolin on behavioral performance in Ts65Dn mice {#sec2-9}
-----------------------------------------------------------

After administration of luteolin for 4 weeks, Morris water maze results showed that compared with the WT + vehicle group ([**Figure 1A**](#F1){ref-type="fig"}), the time to find the hidden platform was longer in the Ts65Dn + vehicle group (*P* \< 0.01). In the spatial exploration test (**Figure** [**1B**](#F1){ref-type="fig"} and [**C**](#F1){ref-type="fig"}), compared with the Ts65Dn + vehicle group, the number of crossings of the target platform/quadrant area was more and the time spent in the platform was longer in the WT + vehicle group (both *P* \< 0.01). These performance deficits indicate defects in learning and memory abilities in Ts65Dn + vehicle mice. After treatment with luteolin, the deficits were partially alleviated, with the time to finding the hidden platform being significantly shortened (*P* \< 0.05). The novel object recognition test ([**Figure 1D**](#F1){ref-type="fig"}) revealed that the discrimination index was significantly lower in the Ts65Dn + vehicle group than in the WT + vehicle group (*P* \< 0.01). In comparison, after luteolin treatment, novel object recognition ability was significantly improved in the mouse model of Down syndrome (*P* \< 0.05).

![Effect of luteolin on behavioral performance in Ts65Dn mice.\
(A) Latency to reach the platform in the Morris water maze test on the last day of testing (genotype (*F* = 23.5, *P* \< 0.01), treatment (*F* = 102.4, *P* \< 0.01), genotype × treatment (*F* = 44, *P* \< 0.01)). (B) Number of entries into the target platform/quadrant area in a period of 60 seconds in the spatial exploration task. Entries into the target quadrant (genotype (*F* = 27.7, *P* \< 0.01), treatment (*F* = 7.5, *P* \< 0.01), genotype × treatment (*F* = 19.6, *P* \< 0.01)). Entries into the platform area (genotype (*F* = 51.5, *P* \< 0.01), treatment (*F* = 28.3, *P* \< 0.01), genotype × treatment (*F* = 9.2, *P* \< 0.01)). (C) Time spent in the target quadrant (genotype (*F* = 42.9, *P* \< 0.01), treatment (*F* = 41.4, *P* \< 0.01), genotype × treatment (*F* = 29.1, *P* \< 0.01)). (D) Discrimination index in the novel object recognition test. Test phase: genotype (*F* = 51.5, *P* \< 0.01), treatment (*F* = 28.3, *P* \< 0.01), genotype × treatment (*F* = 9.2, *P* \< 0.01). Number of animals in each group: WT + vehicle group: *n* = 12; WT + luteolin group: *n* = 11; Ts65Dn + vehicle group: *n* =12; Ts65Dn + luteolin group: *n* = 12. Data are shown as the mean ± SEM (two-way analysis of variance followed by Tukey's *post hoc* test). All experiments were performed more than three times. \**P* \< 0.05, \*\**P* \< 0.01. WT: Wild-type.](NRR-14-613-g002){#F1}

Effect of luteolin on hippocampal cell proliferation in Ts65Dn mice {#sec2-10}
-------------------------------------------------------------------

Compared with the WT + vehicle group, body and brain weights were lower in the Ts65Dn + vehicle group (*P* \< 0.05), suggesting developmental retardation. Luteolin treatment restored the body and brain weights in Ts65Dn mice ([**Figure 2A**](#F2){ref-type="fig"}).

![Effect of luteolin on hippocampal cell proliferation in Ts65Dn mice.\
(A) Body and brain weights after 4-week administration of luteolin. Body weight: genotype (*F* = 7.33, *P* \< 0.01), treatment (*F* = 0.46, *P* = 0.49), genotype × treatment (*F* = 5.86, *P* \< 0.05). Brain weight: genotype (*F* = 4.1, *P* \< 0.05), treatment (*F* = 0.83, *P* = 0.37), genotype × treatment (*F* = 19.6, *P* \< 0.01). (B) Nissl staining of hippocampal tissue. (C) Immunofluorescence for Ki67 (red, TRITC) in the subgranular zone. Scale bars: 20 μm in B, 50 μm in C. (D) Numbers of Ki67^+^ cells in each group: genotype (*F* = 55.4, *P* \< 0.01), treatment (*F* = 77.4, *P* \< 0.05), genotype × treatment (*F* = 51.3, *P* \< 0.01). Number of mice in each group: WT + vehicle group: *n* = 25; WT + luteolin group: *n* = 22; Ts65Dn + vehicle group: *n* = 20; Ts65Dn + luteolin group: *n* = 20. Data are shown as the mean ± SEM (two-way analysis of variance followed by Tukey's *post hoc* test). All experiments were performed more than three times. \**P* \< 0.05, \*\**P* \< 0.01. WT: Wild-type.](NRR-14-613-g003){#F2}

The hippocampus plays an important role in cognition and memory (Contestabile et al., 2013). Nissl bodies in hippocampal neurons in the WT + vehicle group were large and abundant, and pyramidal and glial cells were numerous and distributed in an orderly manner. The number of Nissl bodies in hippocampal neurons in the Ts65Dn + vehicle group was decreased, and the staining was faint and not well defined. The number of Nissl bodies seemed to be increased in the Ts65Dn + luteolin group ([**Figure 2B**](#F2){ref-type="fig"}). As shown in **Figure** [**2C**](#F2){ref-type="fig"} and [**D**](#F2){ref-type="fig"}, immunostaining revealed that the number of Ki67^+^ cells in the hippocampal dentate gyrus was significantly smaller in the Ts65Dn + vehicle group than in the WT + vehicle group (*P* \< 0.01). The number of Ki67^+^ cells was similar in the Ts65Dn + luteolin group and the WT + vehicle group (*P* \> 0.05).

Effects of luteolin on hippocampal neurogenesis in Ts65Dn mice {#sec2-11}
--------------------------------------------------------------

Neural differentiation impairment is thought to be strongly associated with Down syndrome (Dierssen, 2012), and therefore, we examined the expression of some important differentiation markers in the hippocampal dentate gyrus. The expression of the astrocyte marker GFAP (Nimmerjahn, 2009) and the neural stem cell marker nestin (Eisch et al., 2000) were both decreased in the Ts65Dn + vehicle group (**Figure** [**3A**](#F3){ref-type="fig"} and [**B**](#F3){ref-type="fig"}). Furthermore, the immature neuronal marker DCX and the mature neuronal marker NeuN were reduced in the Ts65Dn + vehicle group compared with the WT + vehicle group (*P* \< 0.01). However, the expression levels of all of these markers were increased significantly in the Ts65Dn + luteolin group ([**Figure 3**](#F3){ref-type="fig"}).

![Effects of luteolin on hippocampal neurogenesis in Ts65Dn mice.\
(A) Immunofluorescence labeling for the neural stem cell marker nestin (green, FITC) and the astrocyte marker GFAP (red, TRITC) in the hippocampal dentate gyrus. (B) Mean density of nestin and GFAP immunofluorescence. Nestin: genotype (*F* = 7.47, *P* \< 0.05), treatment (*F* = 6.14, *P* \< 0.05), genotype × treatment (*F* = 12.9, *P* \< 0.01). GFAP: genotype (*F* = 14.1, *P* \< 0.01), treatment (*F* = 12.1, *P* \< 0.01), genotype × treatment (*F* = 10.6, *P* \< 0.01). (C) Immunofluorescence for DCX (red, TRITC) and NeuN (green, FITC). (D) DCX^+^ cell number and NeuN^+^ cell ratios. DCX: genotype (*F* = 19.1, *P* \< 0.01), treatment (*F* = 25.4, *P* \< 0.01), genotype × treatment (*F* = 16.1, *P* \< 0.01). NeuN: genotype (*F* = 30, *P* \< 0.01), treatment (*F* = 22.4, *P* \< 0.01), genotype × treatment (*F* = 15.7, *P* \< 0.01). Scale bars: 20 μm in A and C. Data are shown as the mean ± SEM (two-way analysis of variance followed by Tukey's *post hoc* test). All experiments were performed more than three times. \**P* \< 0.05, \*\**P* \< 0.01. WT: Wild-type; FITC: fluorescein isothiocyanate; GFAP: glial fibrillary acidic protein; DCX: doublecortin.](NRR-14-613-g004){#F3}

Luteolin induces BDNF expression and activates the ERK1/2 pathway in Ts65Dn mice {#sec2-12}
--------------------------------------------------------------------------------

BDNF plays an important role in the survival, differentiation, growth and development of neurons (Lee et al., 2016). Therefore, we examined whether luteolin affects BDNF expression in Ts65Dn mice. Compared with the vehicle group ([**Figure 4A**](#F4){ref-type="fig"}), BDNF expression was increased in the luteolin group (*P* \< 0.05), consistent with previous studies (Bianchi et al., 2010; Stagni et al., 2015). The BDNF/ERK signaling pathway is associated with neuronal differentiation and survival (Lee et al., 2016; Ohta et al., 2017). p-ERK1/2 levels were increased in the Ts65Dn + luteolin group (*P* \< 0.01; **Figure** [**4A**](#F4){ref-type="fig"} and [**B**](#F4){ref-type="fig"}), suggesting that the ERK pathway is activated by luteolin. Furthermore, the increased BDNF expression in the hippocampus might improve learning and memory ability by regulating the growth, proliferation and differentiation of neurons (Peng et al., 2018; Sanna et al., 2018).

![Luteolin increases BDNF expression and activates the ERK1/2 pathway in Ts65Dn mice.\
(A) Western blot assay for BDNF, p-ERK1/2 and total ERK. (B) Relative optical density of BDNF (normalized to GAPDH expression) and the p-ERK/ERK ratio. BDNF: Genotype (*F* = 1.04, *P* = 0.34), treatment (*F* = 24.7, *P* \< 0.01), genotype × treatment (*F* = 0.06, *P* = 0.81). p-ERK/ERK ratio: Genotype (*F* = 2.64, *P* = 0.14), treatment (*F* = 48.6, *P* \< 0.01), genotype × treatment (*F* = 0.16, *P* = 0.71). Data are shown as the mean ± SEM (two-way analysis of variance followed by Tukey's *post hoc* test). All experiments were performed more than three times. \**P* \< 0.05, \*\**P* \< 0.01. WT: Wild-type; BDNF: brain-derived neurotrophic factor; ERK: extracellular signal-regulated kinase; p-ERK: phospho-extracellular signal-regulated kinase; GAPDH: glyceraldehyde-3-phosphate dehydrogenase.](NRR-14-613-g005){#F4}

Discussion {#sec1-4}
==========

Flavonoids have been shown to have therapeutic value in neurodegenerative diseases. For example, 7,8-dihydroxyflavone improves hippocampal neurogenesis and hippocampus-dependent memory *via* the BDNF/TrkB signaling pathway in the Ts65Dn mouse (Lee et al., 2016). Citrus HHMF promotes neurite outgrowth in PC12 cells. Oroxylin A increases BDNF production by activating the MAPK/CREB pathway. Epigallocatechin gallate, a DYRK1A inhibitor, not only rescues cognitive deficits in the Down syndrome mouse model but also in humans (De la Torre et al., 2014).

Although pharmacotherapy has shown promise in the Down syndrome mouse model, safe and effective clinical treatments are still far off. For example, epigallocatechin gallate is still in phase II trials, and its long-term efficacy needs to be assessed (de la Torre et al., 2016). The widely used antidepressant drug fluoxetine was shown to perturb fetal heart development (Reefhuis et al., 2015). Therefore, it is necessary to search for new effective and safe drugs.

Luteolin induces neurite outgrowth, increases expression of GAP-43, a differentiation marker, and activates the ERK1/2 pathway in the PC12 cell line (Lin et al., 2010). In addition, luteolin increases protein kinase A activity in these cells (Lin et al., 2012). Given the beneficial effects of luteolin on neural development, an important feature of this flavonoid is that it can pass through the blood-brain barrier (Dajas et al., 2003). Therefore, in the present study, we treated Ts65Dn mice with luteolin for 4 weeks to assess whether it can improve the hippocampal-dependent behavioral and neurogenetic defects. The Ts65Dn mouse, trisomic for mouse chromosome 16, which contains approximately 92 genes that are orthologous to the Hsa21 genes, is currently the most widely used murine model of Down syndrome, both genetically and phenotypically (Sturgeon and Gardiner, 2011; Antonarakis, 2017). Ts65Dn mice mimic many of the abnormal features of human Down syndrome, including weight loss, craniofacial deformities (Richtsmeier et al., 2000), delay in sensory reaction and motor function (Toso et al., 2008), cognitive and behavioral disorders (Fernandez and Garner, 2008; Belichenko et al., 2009), and a reduction in the number of hippocampal and cerebellar neurons (Moore and Roper, 2007).

Here, we found that behavioral performance in the water maze and novel object recognition test was markedly improved in Ts65Dn mice administrated luteolin. This effect may be associated with changes in hippocampal neurogenesis and neuronal differentiation. The rate of cell proliferation is reduced in the hippocampal subgranular zone of Ts65Dn mice (Contestabile et al., 2013), and a reduced number of Ki67^+^ cells was found in the subgranular zone. However, after luteolin treatment, the reduction was restored. This suggests that luteolin promotes neuronal proliferation. In the hippocampal dentate gyrus, we detected some markers associated with neurogenesis. The intermediate filament protein nestin is mainly expressed in proliferating cells, especially immature nerve precursor cells, and its expression increases during neurogenesis, and therefore, it is considered an important marker of neural stem cells (Li and Chopp, 1999; Eisch et al., 2000). GFAP, a marker of astrocytes, which are widely distributed in various regions of the brain and maintain normal function of neurons, plays an important role in the development, migration and synaptic connections of neurons (Eroglu, 2009; Nimmerjahn, 2009). In this study, the reduced nestin and GFAP expression in the dentate gyrus of Ts65Dn mice, suggestive of impaired neurogenesis, was substantially restored by luteolin.

In the present study, the number of DCX^+^ and NeuN^+^ cells was reduced by 45% and 42%, respectively, in the dentate gyrus of untreated Ts65Dn mice. DCX is a microtubule-related protein that is expressed mainly in immature neurons and plays an important role in cell migration (Manohar et al., 2012). Here, DCX^+^ cells were mainly distributed in the subgranular zone of the dentate gyrus. As NeuN is a specific marker of mature neurons in the granular layer (Dennie et al., 2016), we speculate that the decrease in immature cells in the subgranular zone leads to reduced migration of mature neurons in the granular layer. Luteolin almost completely ameliorated the defect.

Liu et al. (2009) reported that the protective effects of luteolin against amyloid beta toxicity was associated with the increased expression of BNDF in the cerebral cortex of mice. In the present study, luteolin increased the expression of BDNF in the hippocampus of Ts65Dn and WT mice. It has been suggested that the BDNF/ERK signaling pathway may be associated with cell differentiation and survival of immature progenitor neurons (Lee et al., 2016), and luteolin can activate the ERK1/2 signaling pathway (Lin et al., 2010). Here, we found increased levels of p-ERK1/2 in luteolin-treated mice. This suggests that luteolin enhances hippocampal neurogenesis in Ts65Dn mice by activating the BDNF/ERK pathway.

Although luteolin has neuroprotective effects, the underlying mechanisms remain unclear. It was reported that increased levels of free redox-active iron, associated with enhanced lipid peroxidation, may be involved in neurodegeneration and cognitive decline in Down syndrome (Manna et al., 2016). We speculate that the neuroprotective effect of luteolin might be associated with its strong antioxidant capacity, inhibition of neuroinflammation and ferrous ion chelating activity. In addition, the ability of luteolin to increase the expression of neurotrophins might involve estrogen signaling pathways, as the phosphorylated estrogen receptor dimer was previously demonstrated to elevate BDNF mRNA levels (Sohrabji et al., 1995; Moosavi et al., 2016). Furthermore, given its structural similarity to epigallocatechin gallate, luteolin might also activate the hypoxia signal transduction pathway, leading to increased transcription of neurotrophic genes mediating compensatory neuronal survival and differentiation (Weinreb et al., 2009).

A great deal of further study is required to elucidate the mechanisms underlying the neuroprotective effect of luteolin in the Down syndrome mouse model, including its effects on other regions of the brain and hippocampus, and the changes elicited in synaptic plasticity, electrophysiology, and apoptosis. Different luteolin concentrations and treatment durations need to be tested to more thoroughly assess efficacy and safety.

Taken together, our findings show that luteolin protects against behavioral deficits and enhances hippocampal neurogenesis in the mouse model of Down syndrome. Therefore, luteolin may have therapeutic potential for treating neurodegenerative diseases.
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